網膜色素変性症市場：タイプ別、提供品目別、最終用途別-2025-2030年の世界予測

網膜色素変性症市場は、2023年に98億5,000万米ドルと評価され、2024年には106億6,000万米ドルに達すると予測され、CAGR 9.02％で成長し、2030年には180億4,000万米ドルに達すると予測されています。

網膜色素変性症（RP）は、網膜の細胞の破壊と喪失を特徴とする希少遺伝子疾患群であり、多くの場合、視力障害と失明につながります。この市場には、治療薬、補助技術、遺伝学的検査、カウンセリング・サービスが含まれ、この疾患の管理・診断が目的です。この分野の進歩の必要性は、現在の治療法が主に緩和的なものであるため、効果的な治療法が求められていることに起因しています。応用範囲は、遺伝子治療や網膜インプラントなどの薬理学的介入から、技術的に進歩した視覚補助具まで多岐にわたる。最終用途の範囲には、これらのソリューションの展開と開発に積極的に関与している病院、眼科診療所、研究機関が含まれます。

RP市場に影響を与える主な成長要因には、診断能力の向上による有病率の増加、バイオテクノロジーの進歩、遺伝子研究への投資の増加などがあります。CRISPRベースの遺伝子編集や新規ドラッグデリバリーシステムのような革新的治療法の開発は、大きな潜在機会を提供しています。企業は戦略的パートナーシップや共同研究に注力し、研究を加速させ、製品パイプラインを拡大すべきです。しかし、市場の成長は、特に遺伝子治療に関しては、高い治療費、限られた認知度、厳しい規制のハードルといった課題に直面しています。

研究開発の準備が整った革新的な分野には、遺伝子治療、幹細胞治療、装着型視覚補助装置の開発などがあります。これらの分野への取り組みは、市場情勢に大きな影響を与えるブレークスルーにつながる可能性があります。このような試みは、より優れた治療法の開発だけでなく、患者の生活の質を向上させる支援技術の強化においても牽引力を見いだす可能性が高いです。

RP市場は高度に専門化され、やや細分化されているが、研究開発と技術に集中的に投資することで、大きな成長の余地が生まれる可能性があります。患者アクセスを強化する政策を立案し、認知度を高めるための教育キャンペーンと組み合わせることで、既存の制限を緩和し、市場機会をさらに拡大し、持続可能な事業成長に貢献することができます。

市場力学：急速に進化する網膜色素変性症市場の主要市場インサイトを公開

網膜色素変性症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 網膜に影響を及ぼす希少眼疾患の世界の有病率の増加
  • 遺伝子治療と個別化医療の重視の高まり
• 市場抑制要因
  • 網膜色素変性症に必要な治療へのアクセシビリティと手頃な価格
• 市場機会
  • 網膜色素変性症を治療するために新たに開発された医薬品に対する政府の支持的承認
  • 網膜色素変性症を治療するための継続的な治療と診断の進歩
• 市場の課題
  • 疾患に対する認識不足と誤診

ポーターのファイブフォース：網膜色素変性症市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：網膜色素変性症市場における外部からの影響の把握

外部マクロ環境要因は、網膜色素変性症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析網膜色素変性症市場における競合情勢の把握

網膜色素変性症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス網膜色素変性症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、網膜色素変性症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨網膜色素変性症市場における成功への道筋を描く

網膜色素変性症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で網膜に影響を与える稀な眼疾患の罹患率が増加
    • 遺伝子治療と個別化医療への重点の高まり
  • 抑制要因
    • 網膜色素変性症に必要な治療のアクセス性と手頃な価格
  • 機会
    • 治療のための新開発薬に対する政府の支持的な承認網膜色素変性症
    • 治療と診断の継続的な進歩により、網膜色素変性症を治療します
  • 課題
    • 病気に対する認識不足と誤診
• 市場セグメンテーション分析
  • タイプ：常染色体優性網膜色素変性症による網膜色素変性症の急増例
  • 最終用途：専門クリニックの活用の進化網膜色素変性症の治療と管理
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 網膜色素変性症市場：タイプ別

• 常染色体優性網膜色素変性症
• 常染色体劣性網膜色素変性症
• Xリンクされた網膜色素変性症

第7章 網膜色素変性症市場：提供別

• 診断
• 治療

第8章 網膜色素変性症市場：最終用途別

• ホームケア
• 病院
• 専門クリニック

第9章 南北アメリカの網膜色素変性症市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の網膜色素変性症市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの網膜色素変性症市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • jCyteのjCell Therapyが網膜色素変性症の第3相試験に突入
  • ヤンセンがメイラGTx社から先駆的なXLRP遺伝子治療の権利を取得し、網膜疾患の進歩を促進
  • RD基金がNVascの網膜治療における画期的な進歩を支援
• 戦略分析と提言

企業一覧

• 4D Molecular Therapeutics, Inc.
• Astellas Pharma Inc.
• Beacon Therapeutics Limited
• BIOGEN INC.
• Clino Corporation
• Coave Therapeutics SA
• Editas Medicine, Inc.
• GENSIGHT BIOLOGICS
• Genethon
• Johnson & Johnson Services, Inc.
• MeiraGTx Holdings PLC
• Mimetogen Pharmaceuticals
• Nacuity Pharmaceuticals, Inc.
• Novartis AG
• Orphagen Pharmaceuticals, Inc.
• Oxford Biomedica PLC
• Precision BioSciences, Inc.
• ProQR Therapeutics N.V.
• Sanofi S.A.
• Santen Pharmaceutical Co., Ltd.
• Spark Therapeutics, Inc.
• Sun Pharmaceutical Industries Ltd.
• The Wyanoke Group

LIST OF FIGURES

• FIGURE 1. RETINITIS PIGMENTOSA MARKET RESEARCH PROCESS
• FIGURE 2. RETINITIS PIGMENTOSA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RETINITIS PIGMENTOSA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RETINITIS PIGMENTOSA MARKET DYNAMICS
• TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 30. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 45. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 47. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 50. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 100. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 102. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 114. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 117. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023

The Retinitis Pigmentosa Market was valued at USD 9.85 billion in 2023, expected to reach USD 10.66 billion in 2024, and is projected to grow at a CAGR of 9.02%, to USD 18.04 billion by 2030.

Retinitis Pigmentosa (RP) is a group of rare genetic disorders characterized by the breakdown and loss of cells in the retina, which often leads to vision impairment and blindness. The market scope encompasses therapeutics, assistive technologies, and genetic testing and counseling services aimed at managing and diagnosing the condition. The necessity of advancements in this field stems from the demand for effective treatments, as current therapies are primarily palliative. The application scope spans from pharmacological interventions such as gene therapies and retinal implants to technologically advanced visual aids. The end-use scope includes hospitals, eye care clinics, and research institutions that are actively involved in deploying and developing these solutions.

Key growth factors influencing the RP market include increasing prevalence rates due to better diagnostic capabilities, advancements in biotechnology, and rising investment in genetic research. The development of innovative treatments like CRISPR-based gene editing and novel drug delivery systems offers significant potential opportunities. Companies should focus on strategic partnerships and collaborations to accelerate research and expand their product pipelines. However, market growth faces challenges such as high treatment costs, limited awareness, and stringent regulatory hurdles, especially concerning gene therapies.

Innovative areas poised for research and development include gene therapy, stem cell therapy, and development of wearable visual aids. Engaging in these areas may lead to breakthroughs that significantly impact the market landscape. Such endeavors are likely to find traction not only in developing better therapeutic solutions but also in enhancing assistive technologies that improve the quality of life for patients.

While the RP market is highly specialized and somewhat fragmented, focused investment in R&D and technology can provide significant room for growth. Crafting policies that bolster patient access, coupled with educational campaigns to increase awareness, can mitigate existing limitations, further expanding market opportunities and contributing towards sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Retinitis Pigmentosa Market

The Retinitis Pigmentosa Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of rare eye diseases affecting retina worldwide
  • Growing emphasis on genetic therapies and personalized medicine
• Market Restraints
  • Accessibility and affordability of treatments required for retinitis pigmentosa
• Market Opportunities
  • Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
  • Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
• Market Challenges
  • Lack of awareness and misdiagnosis of the condition

Porter's Five Forces: A Strategic Tool for Navigating the Retinitis Pigmentosa Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Retinitis Pigmentosa Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Retinitis Pigmentosa Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Retinitis Pigmentosa Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Retinitis Pigmentosa Market

A detailed market share analysis in the Retinitis Pigmentosa Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Retinitis Pigmentosa Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Retinitis Pigmentosa Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Retinitis Pigmentosa Market

A strategic analysis of the Retinitis Pigmentosa Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Retinitis Pigmentosa Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Astellas Pharma Inc., Beacon Therapeutics Limited, BIOGEN INC., Clino Corporation, Coave Therapeutics SA, Editas Medicine, Inc., GENSIGHT BIOLOGICS, Genethon, Johnson & Johnson Services, Inc., MeiraGTx Holdings PLC, Mimetogen Pharmaceuticals, Nacuity Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Oxford Biomedica PLC, Precision BioSciences, Inc., ProQR Therapeutics N.V., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Spark Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., and The Wyanoke Group.

Market Segmentation & Coverage

This research report categorizes the Retinitis Pigmentosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, and X-linked Retinitis Pigmentosa.
• Based on Offering, market is studied across Diagnosis and Treatment.
• Based on End-use, market is studied across Homecare, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of rare eye diseases affecting retina worldwide
    • 5.1.1.2. Growing emphasis on genetic therapies and personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Accessibility and affordability of treatments required for retinitis pigmentosa
  • 5.1.3. Opportunities
    • 5.1.3.1. Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
    • 5.1.3.2. Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness and misdiagnosis of the condition
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa
  • 5.2.2. End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Retinitis Pigmentosa Market, by Type

• 6.1. Introduction
• 6.2. Autosomal Dominant Retinitis Pigmentosa
• 6.3. Autosomal Recessive Retinitis Pigmentosa
• 6.4. X-linked Retinitis Pigmentosa

7. Retinitis Pigmentosa Market, by Offering

• 7.1. Introduction
• 7.2. Diagnosis
• 7.3. Treatment

8. Retinitis Pigmentosa Market, by End-use

• 8.1. Introduction
• 8.2. Homecare
• 8.3. Hospitals
• 8.4. Specialty Clinics

9. Americas Retinitis Pigmentosa Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Retinitis Pigmentosa Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Retinitis Pigmentosa Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. jCyte's jCell Therapy Enters Phase 3 Trials for Retinitis Pigmentosa
  • 12.3.2. Janssen Acquires Rights to Pioneering XLRP Gene Therapy from MeiraGTx, Catalyzing Advancements in Retinal Diseases
  • 12.3.3. The RD Fund Backs NVasc's Breakthrough in Retinal Therapeutics
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4D Molecular Therapeutics, Inc.
• 2. Astellas Pharma Inc.
• 3. Beacon Therapeutics Limited
• 4. BIOGEN INC.
• 5. Clino Corporation
• 6. Coave Therapeutics SA
• 7. Editas Medicine, Inc.
• 8. GENSIGHT BIOLOGICS
• 9. Genethon
• 10. Johnson & Johnson Services, Inc.
• 11. MeiraGTx Holdings PLC
• 12. Mimetogen Pharmaceuticals
• 13. Nacuity Pharmaceuticals, Inc.
• 14. Novartis AG
• 15. Orphagen Pharmaceuticals, Inc.
• 16. Oxford Biomedica PLC
• 17. Precision BioSciences, Inc.
• 18. ProQR Therapeutics N.V.
• 19. Sanofi S.A.
• 20. Santen Pharmaceutical Co., Ltd.
• 21. Spark Therapeutics, Inc.
• 22. Sun Pharmaceutical Industries Ltd.
• 23. The Wyanoke Group